LIAN - LianBio Stock Price, Fair Value and News
0.28USD0.00Â (0.00%)Market Closed
Market Summary
USD0.280.00
Market Closed0.00%
LIAN Stock Price
View Fullscreen
LIAN RSI Chart
LIAN Valuation
LIAN Price/Earnings (Trailing)
LIAN Profitability
LIAN Fundamentals
LIAN Earnings
Breaking Down LIAN Revenue
Last 30 days
-12.1%
Last 90 days
-92.9%
Trailing 12 Months
-86.3%
How does LIAN drawdown profile look like?
LIAN Financial Health
LIAN Investor Care
Tracking the Latest Insider Buys and Sells of LianBio
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Apr 09, 2024 | gu ehong | back to issuer | -5,724 | 0.32 | -17,889 | interim cfo |
| Feb 15, 2024 | silbermann susan michele | sold (taxes) | -91,477 | 4.76 | -19,218 | - |
| Feb 15, 2024 | silbermann susan michele | acquired | 91,476 | 2.52 | 36,300 | - |
| Feb 15, 2024 | stone adam leo | sold (taxes) | -91,477 | 4.76 | -19,218 | interim ceo |
| Feb 15, 2024 | stone adam leo | acquired | 91,476 | 2.52 | 36,300 | interim ceo |
| Feb 15, 2024 | poukalov konstantin | sold (taxes) | -91,477 | 4.76 | -19,218 | - |
| Feb 15, 2024 | poukalov konstantin | acquired | 91,476 | 2.52 | 36,300 | - |
| Feb 15, 2024 | gianakakos anastasios | sold (taxes) | -91,477 | 4.76 | -19,218 | - |
| Feb 15, 2024 | gianakakos anastasios | acquired | 91,476 | 2.52 | 36,300 | - |
| Feb 15, 2024 | perceptive advisors llc | sold (taxes) | -91,477 | 4.76 | -19,218 | - |
Which funds bought or sold LIAN recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| Apr 19, 2024 | Donald L. Hagan, LLC | sold off | -100 | -92,082 | - | -% |
| Apr 12, 2024 | Vida Ventures Advisors, LLC | sold off | -100 | -10,200,900 | - | -% |
| Feb 26, 2024 | PERCEPTIVE ADVISORS LLC | unchanged | - | 171,494,000 | 257,256,000 | 5.74% |
| Feb 16, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | sold off | -100 | -3,873,000 | - | -% |
| Feb 14, 2024 | TYBOURNE CAPITAL MANAGEMENT (HK) LTD | added | 2.89 | 10,270,700 | 15,193,000 | 2.26% |
| Feb 14, 2024 | CITADEL ADVISORS LLC | sold off | -100 | -756,631 | - | -% |
| Feb 14, 2024 | Royal Bank of Canada | sold off | -100 | - | - | -% |
| Feb 14, 2024 | VIKING GLOBAL INVESTORS LP | unchanged | - | 10,621,200 | 15,931,900 | 0.06% |
| Feb 14, 2024 | TWO SIGMA INVESTMENTS, LP | new | - | 59,411 | 59,411 | -% |
| Feb 14, 2024 | TANG CAPITAL MANAGEMENT LLC | added | 420 | 39,187,500 | 41,869,500 | 3.87% |
Are Funds Buying or Selling LIAN?
Calls
Puts
Net Call Options
No. of Funds
Unveiling LianBio's Major ShareHolders
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 29, 2024 | perceptive advisors llc | 53.4% | 57,850,841 | SC 13D/A | |
| Nov 30, 2023 | tang capital partners lp | 8.6% | 9,320,746 | SC 13D | |
| Nov 01, 2023 | tang capital partners lp | 9.0% | 9,649,019 | SC 13G | |
| Feb 14, 2023 | venrock healthcare capital partners ii, l.p. | 4.4% | 4,793,047 | SC 13G/A | |
| Nov 14, 2022 | ra capital management, l.p. | 0% | 0 | SC 13G/A |
Recent SEC filings of LianBio
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Apr 11, 2024 | 4 | Insider Trading | |
| Mar 21, 2024 | 15-12G | 15-12G | |
| Mar 12, 2024 | S-8 POS | Employee Benefits Plan | |
| Mar 12, 2024 | S-8 POS | Employee Benefits Plan | |
| Mar 12, 2024 | S-8 POS | Employee Benefits Plan | |
| Mar 12, 2024 | POS AM | POS AM | |
| Mar 12, 2024 | F-6 POS | F-6 POS | |
| Mar 12, 2024 | EFFECT | EFFECT | |
| Mar 11, 2024 | 25 | 25 | |
| Feb 29, 2024 | SC 13D/A | 13D - Major Acquisition |
Peers (Alternatives to LianBio)
| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
MRNA | 41.2B | 6.8B | 2.33% | -21.90% | -8.74 | 6.02 | -64.45% | -156.37% |
HILS | 22.4B | 152.6K | -0.77% | 465779.94% | -2.4K | 146.8K | - | -9.98% |
ALNY | 18.4B | 1.8B | -0.30% | -28.67% | -41.79 | 10.06 | 76.23% | 61.08% |
BMRN | 17.4B | 2.4B | 8.14% | -4.26% | 103.61 | 7.18 | 15.42% | 18.43% |
INCY | 11.6B | 3.7B | -9.39% | -31.39% | 19.4 | 3.14 | 8.87% | 75.42% |
| MID-CAP | ||||||||
APLS | 5.9B | 396.6M | -12.04% | -45.12% | -11.11 | 14.81 | 425.83% | 18.94% |
BBIO | 4.5B | - | -13.93% | 67.39% | -6.85 | 60.35 | 54.84% | -34.79% |
AXSM | 3.5B | 270.6M | -9.40% | -0.33% | -14.47 | 12.79 | 440.80% | -27.84% |
ARWR | 2.9B | 240.7M | -12.61% | -20.79% | -9.93 | 12.18 | -1.03% | -92.09% |
ACAD | 2.8B | 726.4M | -6.74% | -16.88% | -45.01 | 3.8 | 40.45% | 71.62% |
| SMALL-CAP | ||||||||
CPRX | 1.7B | 398.2M | -6.36% | -10.84% | 24.31 | 4.36 | 85.90% | -14.05% |
NVAX | 587.8M | 983.7M | -10.64% | -48.02% | -1.08 | 0.6 | -50.36% | 17.16% |
CRBP | 396.0M | 881.7K | 8.01% | 271.09% | -8.88 | 466.16 | -77.61% | -5.33% |
INO | 242.4M | 4.9M | -10.76% | 0.48% | -1.79 | 49.8 | -54.97% | 51.71% |
IBIO | 6.7M | 2.1M | 76.15% | 62.71% | -0.25 | 2.14 | -13.45% | 66.37% |
LianBio News
Latest updates
LianBio Earnings Report: Key Takeaways & Analysis
Balance Sheet
(In Millions)
| Balance Sheet | (In Millions) | ||||||||||
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2020Q4 |
| Assets | -5.7% | 263 | 279 | 303 | 320 | 352 | 372 | 413 | 426 | 142 | 279 |
| Current Assets | -5.6% | 258 | 273 | 296 | 313 | 324 | 344 | 386 | 400 | 121 | 277 |
| Cash Equivalents | -0.6% | 103 | 104 | 102 | 79.00 | 79.00 | 134 | 140 | 248 | 109 | 254 |
| Net PPE | -7.7% | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 1.00 | 1.00 |
| Liabilities | 15.0% | 27.00 | 23.00 | 28.00 | 26.00 | 45.00 | 46.00 | 49.00 | 39.00 | 42.00 | 28.00 |
| Current Liabilities | 18.4% | 26.00 | 22.00 | 26.00 | 24.00 | 22.00 | 22.00 | 25.00 | 15.00 | 22.00 | 6.00 |
| Shareholder's Equity | -20.8% | 202 | 256 | 274 | 260 | 307 | 326 | 365 | 387 | - | - |
| Retained Earnings | -4.7% | -540 | -516 | -494 | -470 | -452 | -430 | -387 | -360 | -339 | -163 |
| Additional Paid-In Capital | 0.6% | 746 | 741 | 737 | 732 | 729 | 724 | 720 | 713 | 42.00 | 31.00 |
| Shares Outstanding | 0.0% | 107 | 107 | 107 | 107 | 108 | 108 | 107 | 107 | 21.00 | 20.00 |
| Minority Interest | 0% | 34.00 | 34.00 | 34.00 | 34.00 | 34.00 | 34.00 | 34.00 | 34.00 | 44.00 | 35.00 |
Cashflow (Last 12 Months)
(In Thousands)
| Cashflow (Quarterly) | (In Thousands) | |||||||||||||
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 |
| Cashflow From Operations | 17.9% | -15,864 | -19,318 | -17,632 | -30,713 | -15,964 | -39,407 | -13,101 | -30,380 | -38,797 | -92,865 | -1,911 | - | - |
| Share Based Compensation | 1.0% | 4,540 | 4,494 | 4,276 | 5,212 | 4,739 | 4,528 | 4,669 | 3,379 | 2,168 | 1,443 | 1,674 | - | - |
| Cashflow From Investing | -29.3% | 15,528 | 21,972 | 40,544 | 10,996 | -38,511 | 33,647 | -75,333 | -155,778 | -92.00 | -38.00 | -29.00 | - | - |
| Cashflow From Financing | - | - | - | - | - | - | 1,710 | - | 305,024 | 5,309 | - | 2,940 | - | - |
LIAN Income Statement
2023-09-30Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
| Operating expenses: | ||||
| Research and development | $ 9,018 | $ 8,258 | $ 29,303 | $ 49,178 |
| General and administrative | 17,283 | 16,291 | 48,011 | 46,930 |
| Total operating expenses | 26,301 | 24,549 | 77,314 | 96,108 |
| Loss from operations | (26,301) | (24,549) | (77,314) | (96,108) |
| Other income: | ||||
| Interest income, net | 2,707 | 1,405 | 7,867 | 2,238 |
| Other income, net | 141 | 1,253 | 966 | 1,873 |
| Net loss before income taxes | (23,453) | (21,891) | (68,481) | (91,997) |
| Income taxes | 586 | 6 | 1,224 | 17 |
| Net loss | (24,039) | (21,897) | (69,705) | (92,014) |
| Other comprehensive income (loss): | ||||
| Foreign currency translation loss, net of tax | (130) | (2,282) | (1,667) | (3,096) |
| Unrealized gain (loss) on marketable securities, net of tax | 236 | (160) | 527 | (1,274) |
| Comprehensive loss | $ (23,933) | $ (24,339) | $ (70,845) | $ (96,384) |
| Net loss per share attributable to ordinary shareholders, basic (in dollars per share) | $ (0.22) | $ (0.20) | $ (0.65) | $ (0.85) |
| Net loss per share attributable to ordinary shareholders, diluted (in dollars per share) | $ (0.22) | $ (0.20) | $ (0.65) | $ (0.85) |
| Weighted-average shares outstanding used in computing net loss per share attributable to ordinary shareholders, basic (in shares) | 107,167,691 | 108,353,831 | 107,164,699 | 107,854,547 |
| Weighted-average shares outstanding used in computing net loss per share attributable to ordinary shareholders, diluted (in shares) | 107,167,691 | 108,353,831 | 107,164,699 | 107,854,547 |
LIAN Balance Sheet
2023-09-30Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 103,457 | $ 79,221 |
| Marketable securities | 148,765 | 223,142 |
| Prepaid expenses and other current assets | 4,673 | 8,640 |
| Other receivable | 910 | 1,770 |
| Total current assets | 257,805 | 312,773 |
| Restricted cash, non-current | 69 | 73 |
| Property and equipment, net | 2,364 | 3,116 |
| Operating lease right-of-use assets | 2,644 | 3,978 |
| Other non-current assets | 20 | 20 |
| Total assets | 262,902 | 319,960 |
| Current liabilities: | ||
| Accounts payable | 6,229 | 1,453 |
| Accrued expenses | 15,882 | 19,826 |
| Current portion of operating lease liabilities | 1,893 | 1,851 |
| Other current liabilities | 1,623 | 485 |
| Total current liabilities | 25,627 | 23,615 |
| Operating lease liabilities | 950 | 2,488 |
| Other liabilities | 213 | 210 |
| Total liabilities | 26,790 | 26,313 |
| Commitments and contingencies (Note 8) | ||
| Shareholders’ equity: | ||
| Ordinary shares, $0.000017100448 par value. 2,923,900,005 shares authorized as of September 30, 2023; 107,168,686 shares issued and outstanding as of September 30, 2023; 2,923,900,005 shares authorized as of December 31, 2022; 107,043,924 shares issued and outstanding as of December 31, 2022 | 2 | 2 |
| Additional paid-in capital | 745,786 | 732,476 |
| Accumulated other comprehensive loss | (3,220) | (2,080) |
| Accumulated deficit | (540,230) | (470,525) |
| Total LianBio shareholders’ equity | 202,338 | 259,873 |
| Non-controlling interest | 33,774 | 33,774 |
| Total shareholders’ equity | 236,112 | 293,647 |
| Total liabilities and shareholders’ equity | $ 262,902 | $ 319,960 |
| Â CEO | Dr. Yizhe Wang Ph.D. |
|---|---|
| Â WEBSITE | lianbio.com |
| Â INDUSTRY | Biotechnology |
| Â EMPLOYEES | 163 |